Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Xiaoqi Liu

doi:10.1016/j.tranon.2015.03.010

Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Xiaoqi Liu

Research output: Contribution to journal › Review article › peer-review

131 Scopus citations

Abstract

Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

Original language	English
Pages (from-to)	185-195
Number of pages	11
Journal	Translational Oncology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.tranon.2015.03.010
State	Published - 2015

Bibliographical note

Funding Information:
Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc, was provided by Katie McClendon of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this review. Boehringer Ingelheim was given the opportunity to review for factual accuracy only. This work was supported by the National Institutes of Health (R01CA157429), the American Cancer Society (RSG-13-073-01-CNE), and the National Science Foundation (1049693-MCB). The author declares no conflicts of interest.

Publisher Copyright:
© 2015 The Authors. Published by Elsevier Inc.

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tranon.2015.03.010

Cite this

@article{b6fa0dbe330644308a42e9a7184001bd,

title = "Targeting polo-like kinases: A promising therapeutic approac for cancer treatment",

abstract = "Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.",

author = "Xiaoqi Liu",

note = "Funding Information: Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc, was provided by Katie McClendon of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this review. Boehringer Ingelheim was given the opportunity to review for factual accuracy only. This work was supported by the National Institutes of Health (R01CA157429), the American Cancer Society (RSG-13-073-01-CNE), and the National Science Foundation (1049693-MCB). The author declares no conflicts of interest. Publisher Copyright: {\textcopyright} 2015 The Authors. Published by Elsevier Inc.",

year = "2015",

doi = "10.1016/j.tranon.2015.03.010",

language = "English",

volume = "8",

pages = "185--195",

number = "3",

}

TY - JOUR

T1 - Targeting polo-like kinases

T2 - A promising therapeutic approac for cancer treatment

AU - Liu, Xiaoqi

N1 - Funding Information: Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals, Inc, was provided by Katie McClendon of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this review. Boehringer Ingelheim was given the opportunity to review for factual accuracy only. This work was supported by the National Institutes of Health (R01CA157429), the American Cancer Society (RSG-13-073-01-CNE), and the National Science Foundation (1049693-MCB). The author declares no conflicts of interest. Publisher Copyright: © 2015 The Authors. Published by Elsevier Inc.

PY - 2015

Y1 - 2015

N2 - Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

AB - Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=84930745615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930745615&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2015.03.010

DO - 10.1016/j.tranon.2015.03.010

M3 - Review article

AN - SCOPUS:84930745615

VL - 8

SP - 185

EP - 195

IS - 3

ER -

Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this